Skip to main content
SpringerLink
Log in

ACE inhibitors and calcium antagonists in the treatment of congestive heart failure

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

The increased mortality after myocardial infarction is related to the risk of reinfarction, sudden death, and the development and progression of heart failure; in congestive heart failure it is due to the progression of heart failure and sudden death. ACE inhibitors have been proven to prevent cardiovascular events, especially the progression of heart failure, in postinfarct patients with reduced ejection fraction and heart failure in the SAVE and AIRE trials. In patients with congestive heart failure, ACE inhibitor treatment has prevented cardiovascular death and reduced morbidity due to progressive heart failure in the SOLVD trials. In post-myocardial infarction patients, the calcium antagonist nifedipine did not affect mortality or morbidity; diltiazem improved prognosis in patients without congestive heart failure and in patients with non-Q-wave infarction; and verapamil improved prognosis by prevention of reinfarction and sudden death. Combination treatment with both verapamil, which has pronounced antiischemic properties and prevents sudden death and reinfarction, and an ACE inhibitor, which prevents the progression of heart failure, is a possibility for future cardiovascular therapy that should be evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. The SOLVD Investigators. The effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med 1991;325:293–302.

    Google Scholar 

  2. The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.N Engl J Med 1992;327:685–691.

    Google Scholar 

  3. McKelvie RM, McConachie D, Yusuf S. Role of angiotensin converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.Eur Heart J 1994;15(Suppl B):9–13.

    Google Scholar 

  4. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.Lancet 1992;340:1173–1178.

    Google Scholar 

  5. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure.N Engl J Med 1987;316:1429–1435.

    Google Scholar 

  6. Pfeffer MA, Braunwald E, Myoe LA, et al. for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med 1992;327:669–677.

    Google Scholar 

  7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.Lancet 1993;342:821–828.

    Google Scholar 

  8. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.Circulation 1990;82:1954–1961.

    Google Scholar 

  9. Packer M. Calcium channel blockers in chronic heart failure. The risk of “physiologically rational” therapy.Circulation 1990;82:2254–2257.

    Google Scholar 

  10. Packer M. Calcium antagonists for congestive heart failure: Evolving concepts in bridge building.Cardiovasc Drugs Ther 1993;7:95–96.

    Google Scholar 

  11. Persson S. Calcium antagonists in secondary prevention after myocardial infarction.Drugs 1991;42(Suppl 2):54–60.

    Google Scholar 

  12. Hansen JF. Secondary prevention with calcium antagonists after an acute myocardial infarction.Drugs 1992;44(Suppl 1):33–43.

    Google Scholar 

  13. Hansen JF. Postinfarct prophylaxis by calcium antagonists. In: Opie LH, ed.Myocardial Protection by Calcium Antagonists. New York: Authors' Publishing House/Wiley-Liss, 1994:98–111.

    Google Scholar 

  14. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina pectoris in light of the second Danish Verapamil Infarction Trial (DAVIT II) and other recent studies.Am J Cardiol 1991;67:1295–1297.

    Google Scholar 

  15. Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction.Eur Heart J 1988;9:354–364.

    Google Scholar 

  16. Mandelzweig L, Goldbourt U, Reicher-Reiss H, Behar S, Kaplinsky E, SPRINT Study Group. Nifedipine does not improve survival in AMI patients without heart failure.Cardiovasc Drugs Ther 1993;7:117–118.

    Google Scholar 

  17. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double blind, randomized multicenter trial.N Engl J Med 1986;315:423–429.

    Google Scholar 

  18. Multicenter Diltiazem Postinfarct Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction.N Engl J Med 1988;319:385–392.

    Google Scholar 

  19. Goldstein RE, Boccuzzi SJ, Cruess D. Diltiazem increases late onset congestive heart failure in postinfarct patients with early reduction in ejection fraction.Circulation 1991;83:52–60.

    Google Scholar 

  20. Gibson RS. Current status of calcium channel-blocking drugs after Q and non-Q-wave myocardial infarction.Circulation 1989;80(Suppl IV):109–119.

    Google Scholar 

  21. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in myocardial infarction.Eur Heart J 1984;5:516–528.

    Google Scholar 

  22. The Danish Study Group on Verapamil in Myocardial Infarction. The effect of verapamil on mortality and major events after acute myocardial infarction. The Danish Verapamil Infarction Trial II–DAVIT II.Am J Cardiol 1990;66:779–785.

    Google Scholar 

  23. The Danish Study Group on Verapamil in Myocardial Infarction. Secondary prevention with verapamil after myocardial infarction.Am J Cardiol 1990;66:33I-40I.

    Google Scholar 

  24. Hansen JF. Verapamil prevents sudden death in patients with increased heart size after an acute myocardial infarction.Cardiovasc Drugs Ther 1993;7:381–382.

    Google Scholar 

  25. Hansen JF. Review of postinfarct treatment with verapamil: Combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction.Cardiovasc Drugs Ther 1994;8:543–547.

    Google Scholar 

  26. Moye LA; Pfeffer MA, Wun CC et al., SAVE Investigators. Uniformity of captopril benefit in the SAVE study: Subgroup analysis.Eur Heart J 1994;15(Suppl B):2–8.

    Google Scholar 

  27. Wallen NH, Held C, Rehnqvist N, Hjelmdahl P. Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris.Am J Cardiol 1975;75:1–6.

    Google Scholar 

  28. Jespersen CM, Hansen JF, Mortensen LS, DAVIT Study Group. The prognostic significance of postinfarct angina pectoris and the effect of verapamil on the incidence of angina pectoris and prognosis.Eur Heart J 1994;15:270–276.

    Google Scholar 

  29. Vaage-Nilsen M, Rasmussen V, Holländer NH, Hansen JF, DAVIT Study Group. Prevalence of transient myocardial ischemia during the first year after a myocardial infarction. Effect of treatment with verapamil.Eur Heart J 1992;13:666–670.

    Google Scholar 

  30. Jespersen CM, DAVIT Study Group. Role of ischemia in post infarct heart failure.Cardiovasc Drugs Ther 1994;8:823–828.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. DAVIT Study Group, Department of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark

    Jørgen Fischer Hansen MD, PhD

Authors
  1. Jørgen Fischer Hansen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hansen, J.F. ACE inhibitors and calcium antagonists in the treatment of congestive heart failure. Cardiovasc Drug Ther 9 (Suppl 3), 503–507 (1995). https://doi.org/10.1007/BF00877862

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00877862

Key Words

Search

Navigation